Cue Biopharma
80 hedge funds and large institutions have $39.7M invested in Cue Biopharma in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
7% more funds holding
Funds holding: 75 → 80 (+5)
2.19% more ownership
Funds ownership: 31.17% → 33.36% (+2.2%)
Holders
80
Holding in Top 10
–
Calls
$769K
Puts
$105K
Top Buyers
| 1 | +$2.64M | |
| 2 | +$554K | |
| 3 | +$541K | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$205K |
| 5 |
Jane Street
New York
|
+$144K |
Top Sellers
| 1 | -$713K | |
| 2 | -$359K | |
| 3 | -$287K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$155K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$129K |